CytoMed Therapeutics Limited (NASDAQ:GDTC) Sees Significant Decline in Short Interest

CytoMed Therapeutics Limited (NASDAQ:GDTC) saw a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 119,300 shares, a decrease of 9.3% from the July 31st total of 131,600 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average daily trading volume, of 65,000 shares, the days-to-cover ratio is presently 1.8 days.

Wall Street Analysts Forecast Growth

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 target price on shares of CytoMed Therapeutics in a research note on Tuesday, June 11th.

CytoMed Therapeutics Stock Up 0.6 %

CytoMed Therapeutics stock traded up $0.01 during trading on Tuesday, hitting $1.49. The company had a trading volume of 1,098 shares, compared to its average volume of 40,322. The company has a quick ratio of 14.09, a current ratio of 14.09 and a debt-to-equity ratio of 0.04. CytoMed Therapeutics has a 1-year low of $1.36 and a 1-year high of $5.50. The company’s 50 day simple moving average is $1.85 and its 200-day simple moving average is $2.03.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.